Organon & Co. (OGN)

Market Cap	3.57B +57.5%
Revenue (ttm)	6.13B -2.5%
Net Income	209.00M -70.1%
EPS	0.79 -70.5%
Shares Out	262.61M
PE Ratio	17.15
Forward PE	3.81
Dividend	$0.08 (0.59%)
Ex-Dividend Date	Aug 14, 2026

Volume	3,332,592
Open	13.57
Previous Close	13.55
Day's Range	13.55 - 13.61
52-Week Range	5.69 - 13.61
Beta	1.52
Analysts	Hold
Price Target	11.25 (-17.28%)
Earnings Date	Jul 31, 2026

About OGN

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN
• Website: https://www.organon.com

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Analyst Summary

According to 5 analysts, the average rating for OGN stock is "Hold." The 12-month stock price target is $11.25, which is a decrease of -17.28% from the latest price.

Price Target

$11.25

(-17.28% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 8, 2026

Data Sources Report a data error